Use of Long-Acting Lipoglycopeptide Antibiotics—Beyond Convenience

This Clinical Insights summarizes the pharmacological characteristics of dalbavancin and oritavancin and evaluates the clinical evidence supporting their use in infections beyond acute bacterial skin and skin structure infections for general internal medicine clinicians.

Corresponding Author: Emily S. Spivak, MD, MHS, Division of Infectious Diseases, Department of Internal Medicine, University of Utah School of Medicine, 30 N Mario Capecchi Dr, Salt Lake City, UT 84112 (emily.spivak@hsc.utah.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.